Cited by 50RNA Interference and Gene DeliveryAdvanced Drug Delivery SystemsRetinal Development and Disorders

Non-viral therapeutic approaches to ocular diseases: An overview and future directions

Open access
Zulliger, Rahel, Conley, Shannon M., Naash, Muna I.·2015·Journal of Controlled Release

Abstract

Currently there are no viable treatment options for patients with debilitating inherited retinal degeneration. The vast variability in disease-inducing mutations and resulting phenotypes has hampered the development of therapeutic interventions. Gene therapy is a logical approach, and recent work has focused on ways to optimize vector design and packaging to promote optimized expression and phenotypic rescue after intraocular delivery. In this review, we discuss ongoing ocular clinical trials, which currently use viral gene delivery, but focus primarily on new advancements in optimizing the efficacy of non-viral gene delivery for ocular diseases. Non-viral delivery systems are highly customizable, allowing functionalization to improve cellular and nuclear uptake, bypassing cellular degradative machinery, and improving gene expression in the nucleus. Non-viral vectors often yield transgene expression levels lower than viral counterparts, however their favorable safety/immune profiles and large DNA capacity (critical for the delivery of large ocular disease genes) make their further development a research priority. Recent work on particle coating and vector engineering presents exciting ways to overcome limitations of transient/low gene expression levels, but also highlights the fact that further refinements are needed before use in the clinic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.10.007

Cites

301 of 301 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Peptide-based nanoparticles target specific cell receptors, disrupt the endosomal membrane, deliver cargo to the nucleus, induce minimal immune response, and can be delivered in higher doses.

    “This has an advantage over other non-viral vectors, as it targets specific cell receptors, disrupts the endosomal membrane, and delivers the cargo to the nucleus. It induces minimal immune response and has the capability to be delivered in higher doses [37].”

    From The Ocular Gene Delivery Landscape (2021) · cites this paper as [37]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [153]Han Z Banworth MJ Makkia R Conley SM Al-Ubaidi MR Cooper MJ Naash MI Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J 2015 Epub ahead of print 02/26/2015 PMC4447225 25713057
  2. [238]Delgado D Gascon AR Del Pozo-Rodriguez A Echevarria E Ruiz de Garibay AP Rodriguez JM Solinis MA Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm 2012 425 35 43 22226874

Cited by

Sorted by citations

Authors
Zulliger, R., Conley, S. M., & Naash, M. I.
Affiliations
  • University of Houston (US)
  • University of Oklahoma Health Sciences Center (US)
Corresponding author
Naash, Muna I.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2015-12
Volume
219
Pages
471-487
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2215305490
Cited by
50
References
301
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 8 · 2018: 5 · 2017: 9 · 2016: 6 · 2015: 1
FWCI
3.02
Type
journal article
Language
en
Open access
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (EY018656, EY22778)
  • Knights Templar Eye Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
Keywords
non-viral gene delivery, ocular gene therapy, inherited retinal degeneration, non-viral vectors, vector engineering, particle coating, transgene expression, nuclear uptake, retinal gene therapy
MeSH terms
Animals, Biological Transport, Cell Nucleus, DNA, Eye Diseases, Humans, Retina, Genetic Therapy, Gene Transfer Techniques, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review